Globe Newswire11.14.18
STRATA Skin Sciences, a medical technology company in dermatology and plastic surgery dedicated to developing, commercializing, and marketing products for the treatment of dermatologic conditions, has launched the new XTRAC S3 308nm Laser. This next-generation XTRAC is smaller, faster, and smarter.
The smaller footprint with a vertical configuration saves valuable floor space, which is at a premium in dermatology offices. Speed drives the S3, which is 20 percent faster than legacy devices, enabling dermatology partner clinics to treat more patients in the same timeframe. Finally, the S3 has a new smart user interface that exclusively pairs with the Optimal Therapeutic Dose approach, allowing the physician to maximize results in the most efficient manner.
The XTRAC S3 first launch site will be with Tareen Dermatology in the Minneapolis, Minn., area. Dr. Mohiba Tareen, medical director for Tareen Dermatology, national dermatology expert for WebMD and an adjunct voluntary faculty at the University of Minnesota, stated, “Since switching to XTRAC lasers, our patients have experienced life-changing improvements with its treatment of their psoriasis, vitiligo and eczema, and this drastic improvement is achieved in significantly fewer treatments. Tareen Dermatology is excited to offer our patients the newest, fastest and the most effective available technology; the new XTRAC S3 is truly state of the art. We appreciate our partnership with STRATA, as it allows us to maximize our utilization though their patient awareness programs and we look forward to expansion into additional offices.”
Dr. Dolev Rafaeli, STRATA’s CEO, stated, “The launch of the new XTRAC S3 device is an important milestone for STRATA, as a first step in a new generation of devices planned to target the specific needs of our partner clinics in the worldwide market. The new device offers a smaller footprint, by as much as 50 percent, delivers faster treatments, which coupled with our newly available MMD diagnostic tip will enhance the patient experience, and offers our providers greater control over treatment effectiveness through the newly designed user interface. The XTRAC S3 platform of devices will allow STRATA to lower material costs and we look forward to our domestic and global deployment of this new generation of excimer lasers which will widen the gap between our current market leading technology and others.”
STRATA Skin Sciences' products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN MicroSystem, marketed specifically for the intended use of micropigmentation. The company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases that impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.
The smaller footprint with a vertical configuration saves valuable floor space, which is at a premium in dermatology offices. Speed drives the S3, which is 20 percent faster than legacy devices, enabling dermatology partner clinics to treat more patients in the same timeframe. Finally, the S3 has a new smart user interface that exclusively pairs with the Optimal Therapeutic Dose approach, allowing the physician to maximize results in the most efficient manner.
The XTRAC S3 first launch site will be with Tareen Dermatology in the Minneapolis, Minn., area. Dr. Mohiba Tareen, medical director for Tareen Dermatology, national dermatology expert for WebMD and an adjunct voluntary faculty at the University of Minnesota, stated, “Since switching to XTRAC lasers, our patients have experienced life-changing improvements with its treatment of their psoriasis, vitiligo and eczema, and this drastic improvement is achieved in significantly fewer treatments. Tareen Dermatology is excited to offer our patients the newest, fastest and the most effective available technology; the new XTRAC S3 is truly state of the art. We appreciate our partnership with STRATA, as it allows us to maximize our utilization though their patient awareness programs and we look forward to expansion into additional offices.”
Dr. Dolev Rafaeli, STRATA’s CEO, stated, “The launch of the new XTRAC S3 device is an important milestone for STRATA, as a first step in a new generation of devices planned to target the specific needs of our partner clinics in the worldwide market. The new device offers a smaller footprint, by as much as 50 percent, delivers faster treatments, which coupled with our newly available MMD diagnostic tip will enhance the patient experience, and offers our providers greater control over treatment effectiveness through the newly designed user interface. The XTRAC S3 platform of devices will allow STRATA to lower material costs and we look forward to our domestic and global deployment of this new generation of excimer lasers which will widen the gap between our current market leading technology and others.”
STRATA Skin Sciences' products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN MicroSystem, marketed specifically for the intended use of micropigmentation. The company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases that impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.